Trial · NCT00456014
Pre-Treatment Positron Emission Topography Scanning for Increasing Success in Antidepressant Treatment
NCT00456014, Not applicable, Completed, New York State Psychiatric Institute; results first posted 2017-06-14
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Pre-Treatment Positron Emission Topography Scanning for Increasing Success in Antidepressant Treatment. Trials, record NCT00456014. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00456014
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Pre-Treatment Positron Emission Topography Scanning for Increasing Success in Antidepressant Treatment
- NCT number
- NCT00456014
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 37 participants, actual
- Lead sponsor
- New York State Psychiatric Institute
- Conditions
- Depression
- Interventions
- Escitalopram, Desipramine
- First posted
- 2007-04-04
- Last updated
- 2019-03-19
- Results first posted
- 2017-06-14
- Limitations and caveats
- small sample size, homogeneity of sample size
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Remission of Depressive Symptoms | Measured at Week 8 | Remission in this study is defined as both a ≥50% decrease in the 24-item Hamilton Depression Rating Scale (HDRS) Score and a final 24-item HDRS score \<10. Remission of depressive symptoms was calculated for the 28 completers of the SSRI phase. |
| Secondary | Remission of Depressive Symptoms - Tricyclic Phase | Measured over 8 weeks | Participants who did not achieve remission during the SSRI phase advanced to the tricyclic phase of the study. Participants were treated with either desipramine or nortriptyline. Seven participants started the tricyclic phase. Four completed the tricyclic phase. The completers (n=4) were analyzed for remission status. |
| Secondary | Improvement in Scores on the Hamilton Depression Rating Scale - SSRI Phase | Measured at Week 8 | Mean % improvement from baseline to end of treatment trial using the 24-item Hamilton Depression Rating Scale. Percent improvement of depressive symptoms was calculated for the 28 completers of the SSRI phase. The higher the score on the 24-item HDRS, the greater the depression severity. Minimum score on the scale is 0, and maximum score is 74. Subscales are not used for this analysis. |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Remission of Depressive Symptoms | Measured at Week 8 | 28 of 38 participants completed the SSRI phase. Only those 28 participants were assessed for remission status.~1 participant who is counted as a non-remitter had a spontaneous remission following his MRI. | participants | NUMBER |
| SECONDARY | Remission of Depressive Symptoms - Tricyclic Phase | Measured over 8 weeks | Depressed participants who did not remit during the SSRI phase advanced to the tricyclic phase of the study. Five participants started treatment with desipramine, one of which also had a trial with nortriptyline. Two participants started tricyclic treatment with nortriptyline. | participants | NUMBER |
| SECONDARY | Improvement in Scores on the Hamilton Depression Rating Scale - SSRI Phase | Measured at Week 8 | Percent improvement of depressive symptoms was calculated for the 28 completers of the SSRI phase. 25 of the 28 SSRI participants completed a trial of escitalopram. 3 of 28 SSRI participants had intolerable side-effects to escitalopram, and were therefore switched to sertraline, and completed a trial of sertraline instead. | % improvement in depression symptoms | MEAN |
Source ClinicalTrials.gov
Results by group6
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Remission of Depressive Symptoms | 1 - SSRI | Participants achieving remission | 14 | participants | |
| Remission of Depressive Symptoms | 1 - SSRI | Participants failing to achieve remission | 14 | participants | |
| Remission of Depressive Symptoms - Tricyclic Phase | Tricyclic Group | Number Achieving Remission | 1 | participants | |
| Remission of Depressive Symptoms - Tricyclic Phase | Tricyclic Group | Numbering Failing to Remit | 3 | participants | |
| Improvement in Scores on the Hamilton Depression Rating Scale - SSRI Phase | 1 - SSRI | Escitalopram Improvement | 45.46 | Standard Deviation 55.95 | % improvement in depression symptoms |
| Improvement in Scores on the Hamilton Depression Rating Scale - SSRI Phase | 1 - SSRI | Sertraline Improvement | 30.01 | Standard Deviation 21.87 | % improvement in depression symptoms |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| SSRI Phase | STARTED | Open Standardized Treatment | 37 | |
| SSRI Phase | COMPLETED | Open Standardized Treatment | 28 | |
| SSRI Phase | NOT COMPLETED | Open Standardized Treatment | 9 | |
| Tricyclic Phase | STARTED | Open Standardized Treatment | 4 | |
| Tricyclic Phase | COMPLETED | Open Standardized Treatment | 1 | |
| Tricyclic Phase | NOT COMPLETED | Open Standardized Treatment | 3 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | 1 - SSRI | ||
| Total, other adverse events | 1 - SSRI | 0 | 37 |
| Total, serious adverse events | 1 - SSRI | 0 | 37 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 23664414 | DERIVED |
Source PubMed
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R01MH074813 | Biological Predictors of Response to Antidepressants | PARSEY, RAMIN V. | COLUMBIA UNIVERSITY HEALTH SCIENCES | NATIONAL INSTITUTE OF MENTAL HEALTH | 2006 to 2010 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00456014
GET https://conductscience.org/api/trials/v1/NCT00456014/registered